Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients.
Identifieur interne : 001439 ( Ncbi/Checkpoint ); précédent : 001438; suivant : 001440Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients.
Auteurs : Christopher G. Goetz [États-Unis] ; Joanne Wuu ; Linda Curgian ; Sue LeurgansSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2006.
English descriptors
- KwdEn :
- Age Factors, Aged, Antiparkinson Agents (adverse effects), Antiparkinson Agents (therapeutic use), Cerebral Cortex (physiopathology), Drug Therapy, Combination, Female, Hallucinations (chemically induced), Hallucinations (diagnosis), Hallucinations (physiopathology), Humans, Interview, Psychological, Levodopa (adverse effects), Levodopa (therapeutic use), Longitudinal Studies, Male, Mental Status Schedule, Middle Aged, Parkinson Disease (diagnosis), Parkinson Disease (drug therapy), Parkinson Disease (physiopathology), Risk Factors.
- MESH :
- chemical , adverse effects : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- chemically induced : Hallucinations.
- diagnosis : Hallucinations, Parkinson Disease.
- drug therapy : Parkinson Disease.
- physiopathology : Cerebral Cortex, Hallucinations, Parkinson Disease.
- Age Factors, Aged, Drug Therapy, Combination, Female, Humans, Interview, Psychological, Longitudinal Studies, Male, Mental Status Schedule, Middle Aged, Risk Factors.
Abstract
The objective of this study was to determine the demographic influences on the sensory characteristics (pure visual vs. nonvisual or mixed visual/nonvisual) of new-onset hallucinations in Parkinson's disease (PD). We utilized 6-year longitudinal interview data from 60 PD patients who had never hallucinated at baseline and reinterviewed them at 6, 18, 48, and 72 months to assess the presence and type of hallucination that developed as the first form of hallucination. We analyzed data by Generalized Estimating Equations methods and by nonparametric tests. Over 6 years, 37 of 60 patients developed hallucinations, and the first hallucinations were pure visual in 18, pure nonvisual in 9, and mixed visual/nonvisual in 10. At the time of first onset of hallucinations, patients whose hallucinations were nonvisual or mixed were significantly older than those with purely visual hallucinations (mean age, 69.8+/-8.3 vs. 61.9+/-10.6; P=0.031). PD duration in the two groups, however, was statistically comparable (9.6+/-4.4 vs. 12.9+/-8.6 years). Though classically described as visual, hallucinations in PD frequently involve other sensory modalities. Age-related disinhibition may facilitate wider cortical activation in PD and potentiate aberrant signaling that invokes other types of hallucinations besides the classic visual forms.
DOI: 10.1002/mds.20701
PubMed: 16161144
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002E73
- to stream PubMed, to step Curation: 002E73
- to stream PubMed, to step Checkpoint: 002E90
- to stream Ncbi, to step Merge: 001439
- to stream Ncbi, to step Curation: 001439
Links to Exploration step
pubmed:16161144Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients.</title>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA. cgoetz@rush.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612</wicri:regionArea>
<wicri:noRegion>Illinois 60612</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wuu, Joanne" sort="Wuu, Joanne" uniqKey="Wuu J" first="Joanne" last="Wuu">Joanne Wuu</name>
</author>
<author><name sortKey="Curgian, Linda" sort="Curgian, Linda" uniqKey="Curgian L" first="Linda" last="Curgian">Linda Curgian</name>
</author>
<author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2006">2006</date>
<idno type="doi">10.1002/mds.20701</idno>
<idno type="RBID">pubmed:16161144</idno>
<idno type="pmid">16161144</idno>
<idno type="wicri:Area/PubMed/Corpus">002E73</idno>
<idno type="wicri:Area/PubMed/Curation">002E73</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002E90</idno>
<idno type="wicri:Area/Ncbi/Merge">001439</idno>
<idno type="wicri:Area/Ncbi/Curation">001439</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001439</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients.</title>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="1"><nlm:affiliation>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612, USA. cgoetz@rush.edu</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois 60612</wicri:regionArea>
<wicri:noRegion>Illinois 60612</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Wuu, Joanne" sort="Wuu, Joanne" uniqKey="Wuu J" first="Joanne" last="Wuu">Joanne Wuu</name>
</author>
<author><name sortKey="Curgian, Linda" sort="Curgian, Linda" uniqKey="Curgian L" first="Linda" last="Curgian">Linda Curgian</name>
</author>
<author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006" type="published">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Age Factors</term>
<term>Aged</term>
<term>Antiparkinson Agents (adverse effects)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Cerebral Cortex (physiopathology)</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Hallucinations (chemically induced)</term>
<term>Hallucinations (diagnosis)</term>
<term>Hallucinations (physiopathology)</term>
<term>Humans</term>
<term>Interview, Psychological</term>
<term>Levodopa (adverse effects)</term>
<term>Levodopa (therapeutic use)</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Mental Status Schedule</term>
<term>Middle Aged</term>
<term>Parkinson Disease (diagnosis)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Risk Factors</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Hallucinations</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Hallucinations</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Cerebral Cortex</term>
<term>Hallucinations</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Age Factors</term>
<term>Aged</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Interview, Psychological</term>
<term>Longitudinal Studies</term>
<term>Male</term>
<term>Mental Status Schedule</term>
<term>Middle Aged</term>
<term>Risk Factors</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study was to determine the demographic influences on the sensory characteristics (pure visual vs. nonvisual or mixed visual/nonvisual) of new-onset hallucinations in Parkinson's disease (PD). We utilized 6-year longitudinal interview data from 60 PD patients who had never hallucinated at baseline and reinterviewed them at 6, 18, 48, and 72 months to assess the presence and type of hallucination that developed as the first form of hallucination. We analyzed data by Generalized Estimating Equations methods and by nonparametric tests. Over 6 years, 37 of 60 patients developed hallucinations, and the first hallucinations were pure visual in 18, pure nonvisual in 9, and mixed visual/nonvisual in 10. At the time of first onset of hallucinations, patients whose hallucinations were nonvisual or mixed were significantly older than those with purely visual hallucinations (mean age, 69.8+/-8.3 vs. 61.9+/-10.6; P=0.031). PD duration in the two groups, however, was statistically comparable (9.6+/-4.4 vs. 12.9+/-8.6 years). Though classically described as visual, hallucinations in PD frequently involve other sensory modalities. Age-related disinhibition may facilitate wider cortical activation in PD and potentiate aberrant signaling that invokes other types of hallucinations besides the classic visual forms.</div>
</front>
</TEI>
<affiliations><list><country><li>États-Unis</li>
</country>
</list>
<tree><noCountry><name sortKey="Curgian, Linda" sort="Curgian, Linda" uniqKey="Curgian L" first="Linda" last="Curgian">Linda Curgian</name>
<name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
<name sortKey="Wuu, Joanne" sort="Wuu, Joanne" uniqKey="Wuu J" first="Joanne" last="Wuu">Joanne Wuu</name>
</noCountry>
<country name="États-Unis"><noRegion><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G" last="Goetz">Christopher G. Goetz</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001439 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd -nk 001439 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Ncbi |étape= Checkpoint |type= RBID |clé= pubmed:16161144 |texte= Age-related influences on the clinical characteristics of new-onset hallucinations in Parkinson's disease patients. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Checkpoint/RBID.i -Sk "pubmed:16161144" \ | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Checkpoint/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |